Myriad Genetics Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Myriad Genetics ont diminué à un taux annuel moyen de -34.2%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 33.8% par an. Les revenus ont augmenté de en à un taux moyen de 6.4% par an.
Informations clés
-34.22%
Taux de croissance des bénéfices
-30.04%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 6.43% |
| Rendement des fonds propres | -118.52% |
| Marge nette | -48.24% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Apr 21
MYGN: 2026 Turnaround And Pipeline Milestones Will Keep Sentiment Cautious
Analyst price targets on Myriad Genetics have moved slightly lower, with recent cuts to $6 from $8 and $6.50, as analysts wait for clearer evidence of progress on the turnaround plan, pipeline milestones, and improved growth and profitability before shifting their stance. Analyst Commentary Recent Street research reflects a cautious stance on Myriad Genetics, with bearish analysts trimming price targets and highlighting execution and growth risks despite some operational positives.Mise à jour du récit • Apr 05
MYGN: 2026 Turnaround Execution And Pipeline Delivery Will Sustain Bearish Caution
Analysts have trimmed their price targets on Myriad Genetics to a range of $6 to $7, reflecting caution around the pace of the turnaround and the need for clearer progress on growth, profitability and pipeline execution before taking a more constructive stance. Analyst Commentary Recent research updates point to a cautious tone, with several bearish analysts trimming price targets into the US$6 to US$7 range and maintaining neutral ratings.Seeking Alpha • Mar 31
Myriad Genetics: SOTP Suggests The Company Is Undervalued
Summary Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside. Near-term catalysts in 2026, including HCT Precise MRD customer testing, the planned AI-enabled Prolaris launch, and continued cost discipline, could help narrow the valuation gap. Read the full article on Seeking AlphaMise à jour du récit • Mar 21
MYGN: Turnaround Execution In 2026 Will Drive Continued Cautious Sentiment
The Street’s blended price target for Myriad Genetics has shifted lower into a $6 to $7 range as analysts factor in updated sector models, reiterated 2026 guidance, and the need for clearer progress on the company’s turnaround and profitability before becoming more constructive. Analyst Commentary Recent research updates show a clear tilt toward caution, with several bearish analysts trimming their valuation ranges for Myriad Genetics and keeping ratings in the middle of the scale rather than moving to a more positive stance.Mise à jour du récit • Mar 06
MYGN: Turnaround Execution And 2026 Pipeline Milestones Will Drive Bearish Outlook
Analysts have trimmed their price targets on Myriad Genetics to a range of about $6 to $7, reflecting more cautious assumptions on growth and profitability even as they acknowledge recent results and the company’s ongoing turnaround efforts. Analyst Commentary Recent research updates show bearish analysts trimming price targets on Myriad Genetics into a tighter band around $6 to $7, signaling a more cautious stance on the stock even as they acknowledge operational progress.Mise à jour du récit • Feb 19
MYGN: Rebased Outlook Weighs Execution Risks Against Upcoming MRD Commercialization Potential
Analysts have adjusted their outlook on Myriad Genetics, trimming the average price target to $7 from $9. They have also updated their assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E based on recent diagnostics sector research and expectations for solid results and 2026 guidance.Article d’analyse • Feb 13
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 27% in the...
Mise à jour du récit • Feb 05
MYGN: Sector Fundamentals And New Diagnostics Partnerships Will Support A More Constructive Outlook
Analysts have lowered their price target on Myriad Genetics to $7 from $9, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, while still expecting solid diagnostics sector results and 2026 outlooks. Analyst Commentary Recent research on Myriad Genetics focuses on how the updated $7 price target lines up with expectations for the broader diagnostics group, where analysts still see solid sector results and 2026 outlooks supported by what they describe as strong fundamentals.Article d’analyse • Feb 04
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Mise à jour du récit • Jan 22
MYGN: Sector Strength And Expanded Cancer Testing Will Support Future Upside
Narrative Update Analysts have adjusted their view on Myriad Genetics, reflected in a higher fair value estimate from $14.33 to $16.06 as they weigh mixed price target moves in recent research and slightly different assumptions for growth, margins, and future P/E. Analyst Commentary Recent Street research on Myriad Genetics presents a mixed but informative picture, with some caution on price targets alongside more constructive adjustments that support the updated fair value estimate.Mise à jour du récit • Jan 08
MYGN: Sector Strength And New Partnerships Will Support A More Constructive Outlook
Narrative Update The analyst price target for Myriad Genetics has shifted modestly lower, with a blended change of roughly $1 across recent moves to $7 and $8. Analysts are factoring in updated diagnostics sector expectations and revising their fair value estimates and P/E outlooks for the company.Mise à jour du récit • Dec 24
MYGN: Rising Margin Visibility Will Support A More Constructive Bullish Outlook
Analysts have raised their price target on Myriad Genetics shares from $6.00 to $8.00, reflecting modest improvements in long term profit margin expectations and valuation assumptions, while maintaining a neutral overall outlook. Analyst Commentary Analyst commentary around the revised price target highlights a generally balanced view, with recognition of incremental progress offset by lingering execution and profitability concerns.Mise à jour du récit • Dec 10
MYGN: Improved Earnings Visibility Will Shape Bullish Outlook
Analysts have modestly raised their price target on Myriad Genetics to $8 from $6, reflecting a slightly higher fair value estimate supported by improved forward price to earnings assumptions and a marginally higher discount rate that still preserves cautious revenue growth expectations. Analyst Commentary Analyst sentiment around Myriad Genetics remains balanced, with the higher price target reflecting modest improvements in forward expectations rather than a decisive shift in outlook.Mise à jour du récit • Nov 26
MYGN: Breast Cancer Risk Collaboration And Margin Gains Will Shape Outlook
Narrative Update on Myriad Genetics Analysts have raised their price target for Myriad Genetics from $6 to $8, citing improved profit margins and modest revenue growth as key drivers for the upward revision. Analyst Commentary Analyst opinions about Myriad Genetics reflect a mix of optimism regarding the company's recent performance and continued caution around potential challenges.Mise à jour du récit • Nov 12
MYGN: Expanded Cancer Testing Is Expected To Drive Future Gains
Narrative Update on Myriad Genetics Analysts have increased their price target for Myriad Genetics from $6 to $8. This adjustment reflects revised expectations based on updates to fair value assessments, discount rates, and future earnings metrics.Mise à jour du récit • Oct 29
Adding Cancer Test Capabilities And Mental Health Data Will Support Long-Term Progress
Analysts have slightly raised their price target for Myriad Genetics to approximately $7.95 from $7.77 per share. They cited modest improvements in expected profit margins and updated assumptions around discount rates.Mise à jour du récit • Oct 14
Expanding Oncology Testing And Genomic Profiling Will Widen Market Reach
Analysts have adjusted their price target for Myriad Genetics upward from $7.38 to $7.77, citing minor improvements in profit margin and future price-to-earnings expectations, even though revenue growth projections have been slightly reduced. What's in the News Myriad Genetics has formed a strategic partnership with SOPHiA GENETICS to develop and globally deploy a liquid biopsy companion diagnostic test for pharmaceutical companies, leveraging both companies' expertise and international networks (Strategic Alliances).Article d’analyse • Sep 30
Estimating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)
Key Insights Myriad Genetics' estimated fair value is US$8.13 based on 2 Stage Free Cash Flow to Equity Myriad...Article d’analyse • Aug 17
Myriad Genetics, Inc. (NASDAQ:MYGN) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:MYGN 1 Year Share Price vs Fair Value Explore Myriad Genetics's Fair Values from the Community and select...Article d’analyse • Jun 25
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares would be relieved that the share price has rebounded 29% in...Article d’analyse • May 09
Lacklustre Performance Is Driving Myriad Genetics, Inc.'s (NASDAQ:MYGN) 48% Price Drop
To the annoyance of some shareholders, Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares are down a considerable 48% in the...
Nouveau récit • Mar 24
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth.Article d’analyse • Mar 16
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31%
Myriad Genetics, Inc. ( NASDAQ:MYGN ) shareholders that were waiting for something to happen have been dealt a blow...Article d’analyse • Feb 26
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results
There's been a notable change in appetite for Myriad Genetics, Inc. ( NASDAQ:MYGN ) shares in the week since its annual...Seeking Alpha • Jan 16
Myriad Genetics: Navigating Through A Setback
Summary Myriad Genetics, Inc.'s stock value has halved recently, despite Q3 results released in early November beating expectations. Management has succeeded in reducing GAAP net losses, but has a new challenge with policy changes from United Healthcare that took effect at the beginning of this year. This has impacted FY2025 initial guidance and cratered the stock over the past nine weeks. Are MYGN shares in the 'buy zone' yet? An analysis of Myriad Genetics follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Jan 08
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$26.22 Current share...Article d’analyse • Nov 13
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that Myriad Genetics, Inc. ( NASDAQ:MYGN ) released its quarterly result to the market...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Myriad Genetics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 829 | -400 | 538 | 106 |
| 31 Dec 25 | 825 | -366 | 538 | 107 |
| 30 Sep 25 | 825 | -400 | 549 | 114 |
| 30 Jun 25 | 833 | -395 | 550 | 114 |
| 31 Mar 25 | 831 | -101 | 555 | 116 |
| 31 Dec 24 | 838 | -127 | 560 | 113 |
| 30 Sep 24 | 824 | -116 | 563 | 102 |
| 30 Jun 24 | 802 | -155 | 560 | 98 |
| 31 Mar 24 | 774 | -235 | 562 | 91 |
| 31 Dec 23 | 753 | -263 | 573 | 89 |
| 30 Sep 23 | 734 | -274 | 587 | 91 |
| 30 Jun 23 | 699 | -248 | 581 | 88 |
| 31 Mar 23 | 695 | -146 | 551 | 87 |
| 31 Dec 22 | 678 | -112 | 515 | 85 |
| 30 Sep 22 | 661 | -77 | 444 | 83 |
| 30 Jun 22 | 672 | -18 | 494 | 81 |
| 31 Mar 22 | 682 | -8 | 513 | 80 |
| 31 Dec 21 | 691 | -27 | 538 | 82 |
| 30 Sep 21 | 684 | -57 | 599 | 80 |
| 30 Jun 21 | 662 | -97 | 542 | 78 |
| 31 Mar 21 | 566 | -148 | 514 | 76 |
| 31 Dec 20 | 557 | -224 | 501 | 73 |
| 30 Sep 20 | 598 | -194 | 499 | 74 |
| 30 Jun 20 | 639 | -199 | 507 | 77 |
| 31 Mar 20 | 761 | -148 | 539 | 81 |
| 31 Dec 19 | 813 | -26 | 546 | 83 |
| 30 Sep 19 | 835 | -15 | 547 | 86 |
| 30 Jun 19 | 851 | 5 | 557 | 86 |
| 31 Mar 19 | 830 | 23 | 512 | 83 |
| 31 Dec 18 | 796 | 26 | 479 | 80 |
| 30 Sep 18 | 767 | 54 | 451 | 74 |
| 30 Jun 18 | 744 | 133 | 435 | 71 |
| 31 Mar 18 | 749 | 130 | 444 | 72 |
| 31 Dec 17 | 763 | 126 | 459 | 71 |
| 30 Sep 17 | 771 | 101 | 472 | 73 |
| 30 Jun 17 | 729 | 17 | 440 | 74 |
| 31 Mar 17 | 757 | 32 | 446 | 75 |
| 31 Dec 16 | 751 | 63 | 414 | 75 |
| 30 Sep 16 | 748 | 94 | 385 | 73 |
| 30 Jun 16 | 741 | 117 | 359 | 71 |
| 31 Mar 16 | 757 | 121 | 349 | 70 |
| 31 Dec 15 | 747 | 108 | 349 | 69 |
| 30 Sep 15 | 738 | 95 | 351 | 70 |
| 30 Jun 15 | 723 | 80 | 366 | 76 |
Des revenus de qualité: MYGN n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: MYGN n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: MYGN n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 34.2% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de MYGN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: MYGN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 43% ).
Rendement des fonds propres
ROE élevé: MYGN a un retour sur capitaux propres négatif ( -118.52% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 11:55 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Myriad Genetics, Inc. est couverte par 37 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jack Meehan | Barclays |
| Derek Taller | Benchmark Company |
| Michael Ryskin | BofA Global Research |